BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30005678)

  • 1. Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.
    Ye H; Desai A; Huang S; Jung D; Champlin R; Zeng D; Yan F; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2018 Jul; 37(1):150. PubMed ID: 30005678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontline Treatment for Older Patients with Mantle Cell Lymphoma.
    Ye H; Desai A; Zeng D; Romaguera J; Wang ML
    Oncologist; 2018 Nov; 23(11):1337-1348. PubMed ID: 29895632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
    Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
    Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Chihara D; Cheah CY; Westin JR; Fayad LE; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak LW; Wang ML; Romaguera JE
    Br J Haematol; 2016 Jan; 172(1):80-8. PubMed ID: 26648336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
    Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
    Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C
    Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
    Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
    Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
    Rule S; Cook G; Russell NH; Hunter A; Robinson S; Morley N; Sureda A; Patrick P; Clifton-Hadley L; Adedayo T; Kirkwood A; Peggs KS
    Br J Haematol; 2019 Mar; 184(6):999-1005. PubMed ID: 30560573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current trials for frontline therapy of mantle cell lymphoma.
    Steiner RE; Romaguera J; Wang M
    J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mantle cell lymphoma: Frontline and salvage therapy.
    Romaguera JE
    Curr Hematol Malig Rep; 2008 Oct; 3(4):204-9. PubMed ID: 20425467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later.
    Fang H; Medeiros LJ; Tang Z; Wang W; Ok CY; Patel KP; Khoury JD; Thakral B
    Ann Diagn Pathol; 2021 Feb; 50():151649. PubMed ID: 33189964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
    Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L; King N; Lechowicz MJ; Lonial S; Sinha R; Flowers CR
    Leuk Lymphoma; 2015 Feb; 56(2):383-9. PubMed ID: 24828864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience.
    Sawalha Y; Hill BT; Rybicki LA; Sun D; Dean RM; Jagadeesh D; Hamilton BK; Gerds AT; Sobecks RM; Andresen S; Liu HK; Majhail NS; Pohlman B; Kalaycio ME; Bolwell BJ; Smith MR
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e95-e102. PubMed ID: 29208403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
    Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
    Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.